Because it is highly expressed in prostate cancer, clinicians use PSMA as a target for imaging techniques and therapies such as lutetium-177 prostate-specific membrane antigen radioligand therapy and actinium-225 prostate-specific membrane antigen radioligand therapy to treat prostate cancer. Here, FOLH1 is linked to prostate cancer.